中药板块9月3日跌1.31%，新天药业领跌，主力资金净流出8.29亿元

Market Overview - The Chinese medicine sector experienced a decline of 1.31% on September 3, with Xintian Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3813.56, down 1.16%, while the Shenzhen Component Index closed at 12472.0, down 0.65% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - ST Xiangxue: Closed at 10.93, up 2.44% with a trading volume of 268,100 shares [1] - Guizhou Sanli: Closed at 12.80, up 1.43% with a trading volume of 84,000 shares [1] - Weikang Pharmaceutical: Closed at 22.99, up 1.10% with a trading volume of 78,800 shares [1] - Significant decliners included: - Xinda Pharmaceutical: Closed at 11.53, down 5.72% with a trading volume of 156,000 shares [2] - Zhendong Pharmaceutical: Closed at 8.21, down 4.53% with a trading volume of 675,200 shares [2] - Tailong Pharmaceutical: Closed at 6.72, down 4.00% with a trading volume of 294,400 shares [2] Capital Flow - The Chinese medicine sector saw a net outflow of 829 million yuan from institutional investors, while retail investors contributed a net inflow of 679 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors increased their positions [2] Individual Stock Capital Flow - Guizhou Sanli had a net inflow of 17.47 million yuan from institutional investors, but a net outflow of 13.66 million yuan from retail investors [3] - Weikang Pharmaceutical experienced a net inflow of 8.62 million yuan from institutional investors, while retail investors withdrew 9.30 million yuan [3] - Other notable stocks with significant capital movements include: - ST Xiangxue: Net inflow of 2.50 million yuan from institutional investors [3] - Yunnan Baiyao: Net inflow of 2.27 million yuan from institutional investors [3]